-
Roussel Uclaf S.A. was a
French pharmaceutical company and one of
several predecessor companies of today's Sanofi. It was the
second largest French pharmaceutical...
-
mifepristone for
personal use in 1989, a
decision supported by
Roussel Uclaf. In 1994,
Roussel Uclaf gave the U.S. drug
rights to the Po****tion
Council in exchange...
-
Julien Gaston Roussel, who was
President and
General Manager of the
Roussel Uclaf Laboratoires Pharmaceutiques, and his wife,
Francine Grinda,
daughter of...
- He
later obtained an MBA at HEC Paris. In
April 1986, he
joined Roussel Uclaf (formerly France's
second largest pharmaceutical company,
until bought by...
-
antiandrogen (NSAA)
which was
initially developed in the 1980s by
Roussel Uclaf, the
French pharmaceutical company from
which it
received its name. It was...
- Roxithromycin's half-life is 12 hours.
French pharmaceutical company Roussel Uclaf first marketed roxithromycin in 1987.
Fischer J,
Ganellin CR (2006). Analogue-based...
-
Predecessors Sanofi-Synthélabo
Aventis Hoechst Rhône-Poulenc C****ella
Roussel Uclaf Marion Merrell Dow CEOs
Chris Viehbacher Olivier Brandicourt Main products...
- of St Ivel;
Patheon UK (pharmaceuticals, on the
former site of
Roussel Uclaf) are on the B4006 in Covingham,
north of Valero, in the east of Swindon...
- preparation]",
published 1969-07-24, ****igned to Roussel-
Uclaf U.S.
patent 3,644,368
Roussel Uclaf Mouzin G,
Cousse H,
Autin JM (1980). "A New, Convenient...
- to Roussel-
Uclaf GB 1024156, "Process for the
preparation of 5-iodo-2'-desoxy-uridine",
published 1966-03-30, ****igned to Roussel-
Uclaf Cheong L, Rich...
